MagSense Technology Animation

. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense®…


Comment on US Preventive Services Task Force Recommendation Statement, "Screening for Ovarian Cancer"

This article represents the viewpoint of management. Background The worldwide incidence of ovarian cancer is 12.6 per 100,000 women. In the year 2006, ovarian…


Investor Update — Corporate Presentation Visuals

Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content…


Magnetic Relaxometry for Cancer Detection

In this second segment of Bob Proulx's presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be…


Introduction to Magnetic Relaxometry

This video (below) captures the opening minutes of CEO Bob Proulx's address to the 2016 NobleCon meeting, where he outlines the medical need for a new cancer…


Imagion Biosystems Identifies Key Operational Objectives

Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves…